Last 24 Hours March 04, 2026 — 41 articles reviewed This cycle’s coverage clustered around two poles of the age spectrum, with a single study in Pediatrics reinforcing that even infrequent adolescent...
Study Published in Pediatrics Finds Infrequent Cannabis Use Can Impact Adolescent …
WHY IT MATTERS: Parents and teens should understand that occasional cannabis use is not a safe middle ground during adolescence, as even infrequent exposure appears linked to real academic and emotional consequences. CLINICAL OVERVIEW: Research published in Pediatrics reinforces longstanding clinical concern that adolescent cannabis exposure does not require heavy or daily use to produce measurable harm. Even low-frequency use, occurring as rarely as once monthly, appears associated with worse academic outcomes and disruptions in emotional regulation and mental health.
Study Published in Pediatrics Finds Infrequent Cannabis Use Can Impact Adolescent …
✦ New CED Clinical Relevance #78 Strong Clinical Relevance High-quality evidence with meaningful patient or clinical significance. PediatricsResearchMental HealthSafety Why This Matters Clinicians should counsel adolescent patients and families that even occasional...
Endocannabinoid System Research: Cannabinoids in Pediatrics
Clinical Takeaway Cannabinoids have been studied across a range of pediatric medical conditions, with evidence spanning interventional trials, observational studies, and surveys. The current body of research reflects growing clinical interest but...
Daily Digest: Last 9 Hours: Cognitive Safety Signals, Adolescent Risk, and the Regulatory Puzzle That Still Defines Cannabis Medicine — March 03, 2026
A synthesis of 14 recently added cannabis articles — key themes, clinical context, and Dr. Caplan’s take.
Endocannabinoid System: Cannabis Use & Child Development
Clinical Takeaway Maternal cannabis use during the peripregnancy period was associated with behavioral and developmental differences in children, with effects varying depending on whether the child showed symptoms of autism spectrum disorder....
Cannabidiol for Lennox-Gastaut: Clinical Trial Evidence
Clinical Takeaway Plant-derived cannabidiol (CBD) oral solution produced meaningful reductions in drop seizures in patients with Lennox-Gastaut syndrome at thresholds below the conventional 50% benchmark used in clinical trials. Caregiver-reported outcomes aligned...
Cannabinoid Clinical Trials: CBD Gel Safety in Fragile X
Clinical Takeaway Transdermal cannabidiol gel (ZYN002) is being studied in an open-label extension trial to assess its long-term safety and tolerability in children and adolescents with Fragile X syndrome, a condition involving...
Cannabinoids for Autism: Clinical Evidence & ASD Research
Clinical Takeaway Several randomized clinical trials have examined cannabis derivatives, including CBD-rich preparations, for core and associated symptoms of autism spectrum disorder, with findings suggesting potential benefits for behavioral challenges, anxiety, and...
Endocannabinoid System Research: Cannabinoids for Children
Clinical Takeaway Cannabinoids have been studied across a range of pediatric medical conditions, with the current evidence base including both interventional trials and real-world observational data. The strongest and most consistent findings...